- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01487005
Cardiovascular Effects of Exposure to Ozone (MOSES)
Multicenter Ozone Study in Elderly Subjects
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This multicenter study will investigate whether short-term exposure of elderly volunteers to ambient levels of O3 in a controlled exposure setting while intermittently exercising causes acute cardiovascular responses. The study is based on the suppositions that: 1) elderly people are a susceptible group for cardiovascular effects; and 2) effects are more likely with exercise.
The study will involve approximately 90 healthy volunteers aged ≥55 and ≤70 who meet strict criteria for inclusion. They will be exposed for 3 hours to clean air, 0.07 ppm O3 (near the current NAAQS), and 0.12 ppm O3 (a level measured in several locations in the US). A suite of cardiovascular and pulmonary endpoints will be measured on the day before the exposure and up to 22 hours after the exposures. The study is being conducted at three centers using a common protocol and common SOPs. Most the endpoints will be analyzed by core laboratories to reduce the variability in the results. A Data Coordination and Analysis Center will assemble all the data generated by the three centers and conduct the statistical analyses on the combined data sets.
The study has 3 main objectives:
- To determine the relationship of altered autonomic balance (measured as changes in heart rate and heart rate variability (HRV)), cardiac arrhythmia, and repolarization and ozone exposure.
- To identify instances of altered systemic vascular function [measured as brachial artery flow-mediated dilation (FMD)without and with nitroglycerin (NTG) when exposed to ozone.
- To identify pro-thrombotic vascular state (measured as increase in von Willebrand factor antigen in blood - primary endpoints) when exposed to ozone.
Additional objectives include:
- To identify any increase in micro particle-associated tissues factor (measured as number of particles and tissue factor activity) and platelet activation) in ozone exposure.
- To identify if markers of systemic oxidative stress and inflammation and any correlation with the cardiovascular effects and degree of airway injury (measured as CC16) and airway inflammatory effects (neutrophils and cytokines in induced sputum) in ozone exposure.
- To determine if cardiovascular effects in ozone exposure are correlated with airway inflammatory effects, but not lung function effects.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
California
-
San Francisco, California, Förenta staterna, 94143
- Rekrytering
- University of California at San Francisco
-
Kontakt:
- Hofer Wong
- Telefonnummer: 415-206-8951
- E-post: howong@sfghoem.ucsf.edu
-
Huvudutredare:
- John Balmes, MD
-
-
Massachusetts
-
Watertown, Massachusetts, Förenta staterna, 02472
- Aktiv, inte rekryterande
- New England Research Institutes, Inc.
-
-
New York
-
Rochester, New York, Förenta staterna, 14642
- Rekrytering
- University of Rochester
-
Kontakt:
- Erika Little
- Telefonnummer: 585-275-4163
- E-post: erika_little@urmc.rochester.edu
-
Huvudutredare:
- Mark Frampton, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- Rekrytering
- University of North Carolina at Chapel Hill
-
Kontakt:
- Martha Almond
- Telefonnummer: 919-966-0759
- E-post: martha_almond@med.unc.edu
-
Huvudutredare:
- Philip Bromberg, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- males and females of all ethnic backgrounds.
- Normal spirometry (FEV1 and FVC >75% of predicted and FEV1/FVC >0.65).
- Ability to complete the exposure exercise regimen chosen to induce a ventilation rate of 15 to 17 L/min/m2 without exceeding 80% of predicted maximal heart rate.
- Normal baseline 12-lead resting ECG, and absence of significant ST depression while performing the 15-minute required level of exercise targeted for the exposure period.
- Subjects must be able to avoid certain medication supplements listed for 1 week before the exposure.
Exclusion Criteria:
- Non-English speaking.
- Including, but not limited to as ascertained by the physicians: Subjects with chronic cardiovascular (such as ischemic heart disease) or respiratory (such as asthma or COPD) disease; diabetes, or other organ or system dysfunction; cerebrovascular disease; active psychiatric disorders that would interfere with the subject's ability to understand and participate in the study. Subjects who have tested positive for a disease that affects the immune system (such as HIV, lymphoma, leukemia) or current drug or alcohol abuse (defined as having more than 3 drinks per day or being unable to abstain from alcohol for 3 days).
- Subjects with atopy or allergic rhinitis will not be excluded as long as they do not require regular treatment with antihistamines or systemic steroids.
- Ever-smokers (smoked tobacco or marijuana during the last five years, or with history of >10 pack year for tobacco or > 1 joint year for marijuana, or living with a smoker who smokes inside the house).
- Subject having plasma cotinine level > 3ng/mL.
- BMI >35 or <18 (35 is the official cut off for class 1 obesity).
- Hypertension (defined as blood pressure >140 systolic or >90diastolic) or on anti-hypertension medications other than diuretics.
- Pregnancy or nursing (breastfeeding).
- On the following medications: prednisone, statins, beta-blockers, anticoagulants, current hormonal therapy, tamoxifen. Subjects will not be asked to discontinue needed prescription medications for the purpose of this study. If any of these medications becomes necessary during the course of the study, the subjects will be excluded. Use of other medications will be considered on an individual basis.
- Subjects taking aspirin or PDE5 inhibitors must be willing to abstain from these medications during the week preceding each exposure.
- Occupational exposures (exposed to high levels of vapors, dust, gases, or fumes on an on-going basis)
Studieplan
Hur är studien utformad?
Designdetaljer
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
|---|
|
elderly subjects
Healthy
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in endothelial function
Tidsram: Baseline (16 hours before exposure) and 4 hours after exposure
|
Brachail artey flow-mediated dilation and nitroglycerin-mediated dilation
|
Baseline (16 hours before exposure) and 4 hours after exposure
|
|
Change in heart rate variability
Tidsram: Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
measured with Holter monitor
|
Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
|
Change in prothrombotic vascular state
Tidsram: Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
Peripheral blood samples will be taken and stored as plasma for measurement of von Willenbrand Factor antigen
|
Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
|
Change in cardiac repolarization
Tidsram: Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
from Holter monitor
|
Baseline (0.5 hours before exposure) and 0.2, 2, and 21.5 after exposure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in markers of systemic inflammation
Tidsram: Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
Peripheral blood samples will be taken and stored as plasma for measurements of inflammatory markers
|
Baseline (17 hour before exposure) and 3.5 and 22 hours after exposure
|
|
Change in lung function
Tidsram: Baseline (0.2 hours before exposure) and 0.5, 3, and 22.5 hours after exposure
|
Spirometry
|
Baseline (0.2 hours before exposure) and 0.5, 3, and 22.5 hours after exposure
|
|
Lung inflammation
Tidsram: 22 hours after exposure
|
A sputum sample will be obtained and stored for measurement of inflammatory mediators
|
22 hours after exposure
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Anne Stoddard, PhD, HealthCore-NERI
Publikationer och användbara länkar
Allmänna publikationer
- Rich DQ, Thurston SW, Balmes JR, Bromberg PA, Arjomandi M, Hazucha MJ, Alexis NE, Ganz P, Zareba W, Thevenet-Morrison K, Koutrakis P, Frampton MW. Do Ambient Ozone or Other Pollutants Modify Effects of Controlled Ozone Exposure on Pulmonary Function? Ann Am Thorac Soc. 2020 May;17(5):563-572. doi: 10.1513/AnnalsATS.201908-597OC.
- Arjomandi M, Balmes JR, Frampton MW, Bromberg P, Rich DQ, Stark P, Alexis NE, Costantini M, Hollenbeck-Pringle D, Dagincourt N, Hazucha MJ. Respiratory Responses to Ozone Exposure. MOSES (The Multicenter Ozone Study in Older Subjects). Am J Respir Crit Care Med. 2018 May 15;197(10):1319-1327. doi: 10.1164/rccm.201708-1613OC.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 10-01-4
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .